This is a medical milestone discovered here in Rochester.
Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study
Despite novel targeted agents, prognosis of metastatic renal cell cancer (RCC) remains poor, and experimental therapeutic strategies are warranted.
...recent advances in relevant biomarkers to predict efficacy of biologic therapies and elaborates on their relevance in the clinical management of patients with solid tumor malignancies.
New investigation results, 'Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma...
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disorder predisposing humans to cutaneous and uterine leiomyomas; in 20% of affected families, type 2 papillary renal cell cancers (PRCCII) also occur with aggressive course and poor prognosis.
The potential for metastasis makes recognition of CHRCC cells in cytologic preparations important for patient surveillance, management, and treatment.
Yusuke Sato of the University of Tokyo presented his work on discovering copy number changes in renal cell carcinoma, with the goal of identifying prognostic parameters for the disease as well as discovering novel molecular targets.
Life-extending drugs granted to a Stanway grandfather with advanced kidney cancer, are to be made available to thousands more patients.
Interview with Michael B. Kastan, M.D., Ph.D., director, Comprehensive Cancer Center, St. Jude Children's Research Hospital
Stand Up To Cancer (SU2C) announced today the second round of awards for its Innovative Research Grants Program (IRG), and named the 13 young scientists that will receive a combined total of $9.74 million over the grants three-year term to conduct high-risk/high-reward translational cancer research.
|NeonCRM by Neon One|